DataM Intelligence retweetet

#MEDIA: Announcing @US_FDA has accepted the application for our dual #immunotherapy combination as a potential first-line treatment option for patients with unresectable or metastatic MSI-H or dMMR #colorectalcancer. bit.ly/41buvYj
English

















